Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin.
Journal
Cancer gene therapy
ISSN: 1476-5500
Titre abrégé: Cancer Gene Ther
Pays: England
ID NLM: 9432230
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
22
04
2021
accepted:
10
08
2021
revised:
12
07
2021
pubmed:
25
8
2021
medline:
22
7
2022
entrez:
24
8
2021
Statut:
ppublish
Résumé
Angiogenesis, the formation of new blood vessels from preexisting ones, is crucial for tumor growth and metastatization, and is considered a promising therapeutic target. Unfortunately, drugs directed against a specific proangiogenic growth factor or receptor turned out to be of limited benefit for oncology patients, likely due to the high biochemical redundancy of the neovascularization process. In this scenario, multitarget compounds that are able to simultaneously tackle different proangiogenic pathways are eagerly awaited. UniPR1331 is a 3β-hydroxy-Δ
Identifiants
pubmed: 34426652
doi: 10.1038/s41417-021-00379-5
pii: 10.1038/s41417-021-00379-5
pmc: PMC9293752
doi:
Substances chimiques
Angiogenesis Inhibitors
0
Ephrins
0
Vascular Endothelial Growth Factor A
0
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
908-917Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Presta M, Dell’Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159–78.
pubmed: 15863032
doi: 10.1016/j.cytogfr.2005.01.004
Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273:114–27.
pubmed: 23216836
doi: 10.1111/joim.12019
Brozzo MS, Bjelic S, Kisko K, Schleier T, Leppanen VM, Alitalo K, et al. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood. 2012;119:1781–8.
pubmed: 22207738
doi: 10.1182/blood-2011-11-390922
Pitulescu ME, Adams RH. Regulation of signaling interactions and receptor endocytosis in growing blood vessels. Cell Adhes Migr. 2014;8:366–77.
doi: 10.4161/19336918.2014.970010
Martiny-Baron G, Holzer P, Billy E, Schnell C, Brueggen J, Ferretti M, et al. The small molecule specific EphB4 kinase inhibitor NVP-BHG712 inhibits VEGF driven angiogenesis. Angiogenesis. 2010;13:259–67.
pubmed: 20803239
pmcid: 2941628
doi: 10.1007/s10456-010-9183-z
Tae N, Lee S, Kim O, Park J, Na S, Lee JH. Syntenin promotes VEGF-induced VEGFR2 endocytosis and angiogenesis by increasing ephrin-B2 function in endothelial cells. Oncotarget. 2017;8:38886–901.
pubmed: 28418925
pmcid: 5503580
doi: 10.18632/oncotarget.16452
Boyd AW, Bartlett PF, Lackmann M. Therapeutic targeting of EPH receptors and their ligands. Nat Rev Drug Discov. 2014;13:39–62.
pubmed: 24378802
doi: 10.1038/nrd4175
Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185–204.
pubmed: 28361267
pmcid: 5439974
doi: 10.1007/s10456-017-9552-y
Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M. Targeting EphA2 in cancer. J Hematol Oncol. 2020;13:114.
pubmed: 32811512
pmcid: 7433191
doi: 10.1186/s13045-020-00944-9
Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 2000;6:1900–8.
pubmed: 10815914
Rusnati M, Presta M. Extracellular angiogenic growth factor interactions: an angiogenesis interactome survey. Endothelium. 2006;13:93–111.
pubmed: 16728328
doi: 10.1080/10623320600698011
Chiodelli P, Bugatti A, Urbinati C, Rusnati M. Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules. 2015;20:6342–88.
pubmed: 25867824
pmcid: 6272510
doi: 10.3390/molecules20046342
Russo M, Giavazzi R. Anti-angiogenesis for cancer: current status and prospects. Thrombosis Res. 2018;164:S3–6.
doi: 10.1016/j.thromres.2018.01.030
Festuccia C, Gravina GL, Giorgio C, Mancini A, Pellegrini C, Colapietro A, et al. UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice. Oncotarget. 2018;9:24347–63.
pubmed: 29849945
pmcid: 5966254
doi: 10.18632/oncotarget.25272
Fujita Y, Abe R, Shimizu H. Clinical approaches toward tumor angiogenesis: past, present and future. Curr Pharm Des. 2008;14:3820–34.
pubmed: 19128235
doi: 10.2174/138161208786898680
Sestito S, Runfola M, Tonelli M, Chiellini G, Rapposelli S. New multitarget approaches in the war against glioblastoma: a mini-perspective. Front Pharmacol. 2018;9:874.
pubmed: 30123135
pmcid: 6085564
doi: 10.3389/fphar.2018.00874
Rusnati M, Urbinati C. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr Pharm Des. 2009;15:2946–57.
pubmed: 19754371
doi: 10.2174/138161209789058156
Pellecchia M. Antagonists of protein-protein interactions made easy? J Med Chem. 2013;56:13–4.
pubmed: 23265190
doi: 10.1021/jm301837n
Giorgio C, Incerti M, Pala D, Russo S, Chiodelli P, Rusnati M, et al. Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice. Pharmacol Res. 2019;141:319–30.
pubmed: 30625359
doi: 10.1016/j.phrs.2019.01.011
Giorgio C, Incerti M, Corrado M, Rusnati M, Chiodelli P, Russo S, et al. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochem Pharmacol. 2018;147:21–9.
pubmed: 29129483
doi: 10.1016/j.bcp.2017.11.002
Giorgio C, Russo S, Incerti M, Bugatti A, Vacondio F, Barocelli E, et al. Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis. Biochem Pharmacol. 2016;99:18–30.
pubmed: 26462575
doi: 10.1016/j.bcp.2015.10.006
Castelli R, Tognolini M, Vacondio F, Incerti M, Pala D, Callegari D, et al. Delta(5)-cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system. Eur J Med Chem. 2015;103:312–24.
pubmed: 26363867
doi: 10.1016/j.ejmech.2015.08.048
Chiodelli P, Urbinati C, Mitola S, Tanghetti E, Rusnati M. Sialic acid associated with alphavbeta3 integrin mediates HIV-1 Tat protein interaction and endothelial cell proangiogenic activation. J Biol Chem. 2012;287:20456–66.
pubmed: 22528484
pmcid: 3370225
doi: 10.1074/jbc.M111.337139
Bugatti A, Giagulli C, Urbinati C, Caccuri F, Chiodelli P, Oreste P, et al. Molecular interaction studies of HIV-1 matrix protein p17 and heparin: identification of the heparin-binding motif of p17 as a target for the development of multitarget antagonists. J Biol Chem. 2013;288:1150–61.
pubmed: 23166320
doi: 10.1074/jbc.M112.400077
Tognolini M, Giorgio C, Hassan Mohamed I, Barocelli E, Calani L, Reynaud E, et al. Perturbation of the EphA2-EphrinA1 system in human prostate cancer cells by colonic (poly)phenol catabolites. J Agric Food Chem. 2012;60:8877–84.
pubmed: 22409255
doi: 10.1021/jf205305m
Chiodelli P, Mitola S, Ravelli C, Oreste P, Rusnati M, Presta M. Heparan sulfate proteoglycans mediate the angiogenic activity of the vascular endothelial growth factor receptor-2 agonist gremlin. Arterioscle, Thrombosis, Vasc Biol. 2011;31:e116–27.
doi: 10.1161/ATVBAHA.111.235184
Esko JD. Genetic analysis of proteoglycan structure, function and metabolism. Curr Opin Cell Biol. 1991;3:805–16.
pubmed: 1931081
doi: 10.1016/0955-0674(91)90054-3
Chiodelli P, Rezzola S, Urbinati C, Federici Signori F, Monti E, Ronca R, et al. Contribution of vascular endothelial growth factor receptor-2 sialylation to the process of angiogenesis. Oncogene. 2017;36:6531–41.
pubmed: 28783175
doi: 10.1038/onc.2017.243
Jensen RL. Growth factor-mediated angiogenesis in the malignant progression of glial tumors: a review. Surg Neurol. 1998;49:189–95.
pubmed: 9457270
doi: 10.1016/S0090-3019(97)00218-8
Westerfiled M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). 4th ed. Univ. of Oregon Press, Eugene. 2010.
Nicoli S, De Sena G, Presta M. Fibroblast growth factor 2-induced angiogenesis in zebrafish: the zebrafish yolk membrane (ZFYM) angiogenesis assay. J Cell Mol Med. 2009;13:2061–8.
pubmed: 18657228
doi: 10.1111/j.1582-4934.2008.00432.x
Leppanen VM, Prota AE, Jeltsch M, Anisimov A, Kalkkinen N, Strandin T, et al. Structural determinants of growth factor binding and specificity by VEGF receptor 2. Proc Natl Acad Sci USA. 2010;107:2425–30.
pubmed: 20145116
pmcid: 2823880
doi: 10.1073/pnas.0914318107
Grunewald FS, Prota AE, Giese A, Ballmer-Hofer K. Structure-function analysis of VEGF receptor activation and the role of coreceptors in angiogenic signaling. Biochim Biophys Acta. 2010;1804:567–80.
pubmed: 19761875
doi: 10.1016/j.bbapap.2009.09.002
Rezzola S, Dal Monte M, Belleri M, Bugatti A, Chiodelli P, Corsini M, et al. Therapeutic potential of anti-angiogenic multitarget N,O-sulfated E. Coli K5 polysaccharide in diabetic retinopathy. Diabetes. 2015;64:2581–92.
pubmed: 25695948
doi: 10.2337/db14-1378
Gourlaouen M, Welti JC, Vasudev NS, Reynolds AR. Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells. J Biol Chem. 2013;288:7467–80.
pubmed: 23341459
pmcid: 3597788
doi: 10.1074/jbc.M112.446401
Santos SC, Miguel C, Domingues I, Calado A, Zhu Z, Wu Y, et al. VEGF and VEGFR-2 (KDR) internalization is required for endothelial recovery during wound healing. Exp Cell Res. 2007;313:1561–74.
pubmed: 17382929
doi: 10.1016/j.yexcr.2007.02.020
Hamaoka Y, Negishi M, Katoh H. Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation. Biochem Biophys Res Commun. 2018;499:920–6.
pubmed: 29626472
doi: 10.1016/j.bbrc.2018.04.020
Tang FY, Chiang EP, Shih CJ. Green tea catechin inhibits ephrin-A1-mediated cell migration and angiogenesis of human umbilical vein endothelial cells. J Nutr Biochem. 2007;18:391–9.
pubmed: 17049832
doi: 10.1016/j.jnutbio.2006.07.004
Lin Y, Zhai E, Liao B, Xu L, Zhang X, Peng S, et al. Autocrine VEGF signaling promotes cell proliferation through a PLC-dependent pathway and modulates apatinib treatment efficacy in gastric cancer. Oncotarget. 2017;8:11990–2002.
pubmed: 28061477
pmcid: 5355320
doi: 10.18632/oncotarget.14467
Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM. Regulation of microvascular permeability by vascular endothelial growth factors. J Anat. 2002;200:581–97.
pubmed: 12162726
pmcid: 1570751
doi: 10.1046/j.1469-7580.2002.00066.x
Gavard J. Endothelial permeability and VE-cadherin: a wacky comradeship. Cell Adhes Migr. 2014;8:158–64.
doi: 10.4161/cam.29026
Gavard J, Gutkind JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol. 2006;8:1223–34.
pubmed: 17060906
doi: 10.1038/ncb1486
De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457–74.
pubmed: 28706266
doi: 10.1038/nrc.2017.51
Lauder H, Frost EE, Hiley CR, Fan TP. Quantification of the repair process involved in the repair of a cell monolayer using an in vitro model of mechanical injury. Angiogenesis. 1998;2:67–80.
pubmed: 14517377
doi: 10.1023/A:1009006527462
Peverali FA, Mandriota SJ, Ciana P, Marelli R, Quax P, Rifkin DB, et al. Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells. J Cell Physiol. 1994;161:1–14.
pubmed: 7523424
doi: 10.1002/jcp.1041610102
Tobia C, De Sena G, Presta M. Zebrafish embryo, a tool to study tumor angiogenesis. Int J Dev Biol. 2011;55:505–9.
pubmed: 21858773
doi: 10.1387/ijdb.103238ct
Lodola A, Giorgio C, Incerti M, Zanotti I, Tognolini M. Targeting Eph/ephrin system in cancer therapy. Eur J Med Chem. 2017;142:152–62.
pubmed: 28780190
doi: 10.1016/j.ejmech.2017.07.029
Zhang XY, Zhang PY. Combinations in multimodality treatments and clinical outcomes during cancer. Oncol Lett. 2016;12:4301–4.
pubmed: 28101195
pmcid: 5228028
doi: 10.3892/ol.2016.5242
John A, Qin B, Kalari KR, Wang L, Yu J. Patient-specific multi-omics models and the application in personalized combination therapy. Future Oncol. 2020;16:1737–50.
pubmed: 32462937
Chen JC, Chang YW, Hong CC, Yu YH, Su JL. The role of the VEGF-C/VEGFRs axis in tumor progression and therapy. Int J Mol Sci. 2012;14:88–107.
pubmed: 23344023
pmcid: 3565253
doi: 10.3390/ijms14010088
Chen Y, Zhang H, Zhang Y. Targeting receptor tyrosine kinase EphB4 in cancer therapy. Semin Cancer Biol. 2019;56:37–46.
pubmed: 28993206
doi: 10.1016/j.semcancer.2017.10.002
Pasquale EB. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer. 2010;10:165–80.
pubmed: 20179713
pmcid: 2921274
doi: 10.1038/nrc2806
Groppa E, Brkic S, Uccelli A, Wirth G, Korpisalo-Pirinen P, Filippova M, et al. EphrinB2/EphB4 signaling regulates non-sprouting angiogenesis by VEGF. EMBO Rep. 2018;19:e45054.
Sawamiphak S, Seidel S, Essmann CL, Wilkinson GA, Pitulescu ME, Acker T, et al. Ephrin-B2 regulates VEGFR2 function in developmental and tumour angiogenesis. Nature. 2010;465:487–91.
pubmed: 20445540
doi: 10.1038/nature08995
Chrencik JE, Brooun A, Recht MI, Kraus ML, Koolpe M, Kolatkar AR, et al. Structure and thermodynamic characterization of the EphB4/ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure. 2006;14:321–30.
pubmed: 16472751
doi: 10.1016/j.str.2005.11.011
Basagiannis D, Zografou S, Galanopoulou K, Christoforidis S. Dynasore impairs VEGFR2 signalling in an endocytosis-independent manner. Sci Rep. 2017;7:45035.
pubmed: 28327657
pmcid: 5361198
doi: 10.1038/srep45035
Li H, Nelson CE, Evans BC, Duvall CL. Delivery of intracellular-acting biologics in pro-apoptotic therapies. Curr Pharm Des. 2011;17:293–319.
pubmed: 21348831
pmcid: 3564970
doi: 10.2174/138161211795049642
Yang S, Mao Y, Zhang H, Xu Y, An J, Huang Z. The chemical biology of apoptosis: revisited after 17 years. Eur J Med Chem. 2019;177:63–75.
pubmed: 31129454
doi: 10.1016/j.ejmech.2019.05.019
Kim MM, Umemura Y, Leung D. Bevacizumab and glioblastoma: past, present, and future directions. Cancer J. 2018;24:180–6.
pubmed: 30119081
doi: 10.1097/PPO.0000000000000326
Semeraro F, Morescalchi F, Cancarini A, Russo A, Rezzola S, Costagliola C. Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. Diabetes Metab. 2019;45:517–27.
pubmed: 31005756
doi: 10.1016/j.diabet.2019.04.002
Shim JW, Madsen JR. VEGF signaling in neurological disorders. Int J Mol Sci. 2018;19:275.
Carpenter TC, Schroeder W, Stenmark KR, Schmidt EP. Eph-A2 promotes permeability and inflammatory responses to bleomycin-induced lung injury. Am J Respir Cell Mol Biol. 2012;46:40–7.
pubmed: 21799118
pmcid: 3262654
doi: 10.1165/rcmb.2011-0044OC
Aguilar-Cazares D, Chavez-Dominguez R, Carlos-Reyes A, Lopez-Camarillo C, Hernadez de la Cruz ON, Lopez-Gonzalez JS. Contribution of angiogenesis to inflammation and cancer. Front Oncol. 2019;9:1399.
pubmed: 31921656
pmcid: 6920210
doi: 10.3389/fonc.2019.01399
di Somma M, Vliora M, Grillo E, Castro B, Dakou E, Schaafsma W, et al. Role of VEGFs in metabolic disorders. Angiogenesis. 2020;23:119–30.
pubmed: 31853841
doi: 10.1007/s10456-019-09700-1
Liu H, Devraj K, Moller K, Liebner S, Hecker M, Korff T. EphrinB-mediated reverse signalling controls junctional integrity and pro-inflammatory differentiation of endothelial cells. Thrombosis Haemost. 2014;112:151–63.
doi: 10.1160/TH13-12-1034
Chen F, Liu Z, Peng W, Gao Z, Ouyang H, Yan T, et al. Activation of EphA4 induced by EphrinA1 exacerbates disruption of the blood-brain barrier following cerebral ischemia-reperfusion via the Rho/ROCK signaling pathway. Exp Ther Med. 2018;16:2651–8.
pubmed: 30186497
pmcid: 6122430
Gu S, Fu WY, Fu AKY, Tong EPS, Ip FCF, Huang X, et al. Identification of new EphA4 inhibitors by virtual screening of FDA-approved drugs. Sci Rep. 2018;8:7377.
pubmed: 29743517
pmcid: 5943255
doi: 10.1038/s41598-018-25790-1